MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10378479" target="_blank" >RIV/00216208:11110/18:10378479 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/18:00106934 RIV/00209805:_____/18:00078076 RIV/00064190:_____/18:N0000012
Result on the web
<a href="https://doi.org/10.1515/cclm-2017-0861" target="_blank" >https://doi.org/10.1515/cclm-2017-0861</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1515/cclm-2017-0861" target="_blank" >10.1515/cclm-2017-0861</a>
Alternative languages
Result language
angličtina
Original language name
MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
Original language description
Renal cell carcinoma (RCC) accounts for 2%-3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miR-NAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV15-34678A" target="_blank" >NV15-34678A: Prognostic and predictive molecular factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Chemistry and Laboratory Medicine
ISSN
1434-6621
e-ISSN
—
Volume of the periodical
56
Issue of the periodical within the volume
9
Country of publishing house
DE - GERMANY
Number of pages
6
Pages from-to
1426-1431
UT code for WoS article
000440934600017
EID of the result in the Scopus database
2-s2.0-85042377638